<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00475358</url>
  </required_header>
  <id_info>
    <org_study_id>6231</org_study_id>
    <secondary_id>F1J-MC-SBBT</secondary_id>
    <nct_id>NCT00475358</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Stress Urinary Incontinence Study</brief_title>
  <official_title>Efficacy and Safety of Duloxetine Compared With Placebo in Subjects With Stress Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <brief_summary>
    <textblock>
      Study F1J-MC-SBBT will examine the effect of duloxetine treatment in women with SUI. The
      inclusion and exclusion criteria of this Phase 3 study will ensure that all subjects have a
      clinical diagnosis of SUI.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">February 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess efficacy of duloxetine 80 mg/day for 8 weeks in women with stress urinary incontinence (SUI) compared with placebo as measured by percent change in incontinence episode frequency from baseline.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the efficacy of duloxetine with that of placebo as measured by the change in the disease-specific quality of life instrument (I QOL) scores from baseline to endpoint.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the efficacy of duloxetine with that of placebo in subject perceived improvement in SUI as measured by the Patientâ€™s Global Impressions of Improvement (PGI I) questionnaire.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the safety of duloxetine with that of placebo in the treatment of SUI based on vital signs, laboratory values, and the occurrence of treatment-emergent adverse events (TEAEs).</measure>
  </secondary_outcome>
  <enrollment>120</enrollment>
  <condition>Urinary Incontinence, Stress</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are greater than 20 years of age.

          -  Are female outpatients.

          -  Present with SUI based on the disease diagnostic criteria, average at least one
             incontinent episode per day on the screening diary, and have had symptoms of SUI for a
             minimum of 3 months prior to study entry.

          -  Are women of non-childbearing potential by reason of hysterectomy, other surgery, or
             natural menopause, or are women of childbearing potential who test negative for
             pregnancy at the time of enrollment based on a urine pregnancy test and agree to use a
             medically accepted means of contraception (for example, intrauterine device [IUD],
             oral or injectable contraceptives, implant, barrier device, sterilization, abstinence,
             or sex with a vasectomized male partner) for the duration of the study. Women using
             oral contraceptives or hormone replacement therapy must have a stable dose and regimen
             for greater than or equal to 3 months prior to entry into the study.

          -  Have no language barrier, agree to comply with the requirements of the protocol, and
             sign a written informed consent document prior to entry into the study.

        Exclusion Criteria:

          -  Suffer from severe constipation (for example, have impacted rectum at time of physical
             examination despite recent evacuation).

          -  Has a physical examination, neurological and/or vaginal examination results which, in
             the opinion of the investigator, should exclude the subject.

          -  Are on a medication regimen (including diuretics) for which dose and/or frequency has
             not been stable for at least 12 weeks prior to randomization, or is anticipated to
             change during the course of the study.

          -  Have had any major inpatient surgery within 3 months prior to study entry.

          -  Have current diagnosis of any of the following conditions, disorders, or diseases of
             the genito-urinary tract: Ureteric, bladder, urethral, or rectal fistula

          -  Uncorrected congenital abnormality leading to urinary incontinence

          -  Detrusor instability or noncompliant bladder

          -  Adult enuresis

          -  Voiding difficulty (i.e., subject complains of difficulty emptying their bladder).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tao-Yuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>May 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2007</study_first_submitted>
  <study_first_submitted_qc>May 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2007</study_first_posted>
  <last_update_submitted>May 16, 2007</last_update_submitted>
  <last_update_submitted_qc>May 16, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

